PTC Therapeutics reports Q4 Sephience revenue of $92.5 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
January 12, 2026 8:30 AM ESTStrong Sephience (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M
Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance
2026 product revenue guidance of $700 800M, representing 19 36% year-over-year growth
Strong cash position of approximately $1.94B as of December 31
WARREN, N.J., Jan. 12, 2026 /PRNewswire/ --Â PTC... More
